Kuehn law encourages investors of axsome therapeutics, inc. to contact law firm

New york , april 8, 2025 /prnewswire/ -- kuehn law, pllc, a shareholder litigation law firm, is investigating whether certain officers and directors of axsome therapeutics, inc. (nasdaq: axsm)  breached their fiduciary duties to shareholders.  according to a federal securities lawsuit, insiders at axsome caused the company to misrepresent or fail to disclose (i) axsome's chemistry, manufacturing, and control ("cmc") practices were deficient with respect to axs-07 and its manufacturing process; (ii) as a result, axsome was unlikely to submit the axs-07 nda on its initially represented timeline; (iii) the foregoing cmc issues remained unresolved at the time that the fda reviewed the axs-07 nda; (iv) accordingly, the fda was unlikely to approve the axs-07 nda; (v) as a result of all the foregoing, axsome had overstated axs-07's regulatory and commercial prospects; and (vi) as a result, the company's public statements were materially false and misleading at all relevant times.
AXS Ratings Summary
AXS Quant Ranking